Inactivation and loss of RB1 results in overexpression of HELLS and increased proliferation of retinoblastoma tumors; HELLS has therefore emerged as a potential new therapeutic target for retinoblastoma [47,49]. The gene discussed is RB1; the disease is retinoblastoma.